Introduction
➤ The purpose of this guideline is to update recommendations of the
American Society of Clinical Oncology (ASCO) systemic therapy for
hormone receptor (HR)-positive metastatic breast cancer (MBC) guideline.
a
➤ Specifically, it:
• provides a new recommendation for the use of alpelisib in the treatment of patients
with hormone receptor-positive metastatic breast cancer
• addresses the role of biomarkers in treatment selection for this patient population and
• amends prior recommendations concerning the use of CDK4/6 inhibitors in the
treatment of these patients.
➤ Note that this guideline provides recommendations for endocrine therapy
and targeted therapy, including CDK 4/6 and PI3 kinase inhibition
for hormone receptor-positive metastatic breast cancer patients. A
companion guideline
b
provides recommendations for use of chemo-and
targeted therapy for patients with HER2-negative metastatic breast cancer
that is either endocrine-pretreated or hormone receptor-negative
a
Rugo HS, et al. J Clin Oncol 34:3069-103, 2016.
b
Moy B et al. J Clin Oncol. doi:10.1200/JCO.21.01374.